Netia Medical Technologies, based in Omaha, Nebraska, is dedicated to revolutionizing drug development through its innovative RNAi platform. The company's core mission is to provide cost-effective, faster, and versatile pharmaceutical solutions by licensing its patented single-strand RNAi drug development technology. This platform significantly reduces the time and cost required to bring new drugs to market, making it a valuable asset for pharmaceutical companies and academic groups focused on translational research.

Netia's technology is supported by six patent filings and has the potential to address 'undruggable' targets, thereby expanding the scope of treatable conditions. The company has garnered attention for its ability to cut conventional drug development costs by more than half and reduce the time to market by three years. This impact positions Netia as a transformative player in the pharmaceutical industry, driving advancements in medical research and therapeutic solutions.